2,3,4-tri-O-acetyl-β-D-glucuronic acid methyl ester | 77668-10-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2,3,4-tri-O-acetyl-β-D-glucuronic acid methyl ester
• 英文别名: methyl 2,3,4-tri-O-acetyl-D-glucuronate；methyl tri-O-acetylglucuronate；methyl 2,3,4-tri-O-acetylglucuronate；tri-O-acetyl methyl glucuronate；methyl-2,3,4-tri-O-acetylglucuronate；methyl (2S,3R,4S,5R)-3,4,5-triacetyloxy-2-hydroxy-6-oxohexanoate
• CAS: 77668-10-1
• 化学式: C₁₃H₁₈O₁₀
• 分子量: 334.28
• InChiKey: MSZWKQNQZAXGSX-NNYUYHANSA-N

物化性质

• 熔点：
  188-189 °C
• 沸点：
  458.8±45.0 °C(Predicted)
• 密度：
  1.319±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  23
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  143
• 氢给体数：
  1
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  2,3,4-tri-O-acetyl-β-D-glucuronic acid methyl ester 在 三氟化硼乙醚 作用下， 以 二氯甲烷 为溶剂， 反应 27.5h， 生成
  参考文献：
  名称：

  基于天然抗生素多卡霉素的前药的合成和生物学评价，用于ADEPT和PMT

  摘要：

  恶性肿瘤的化学疗法通常伴随着严重的副作用，因为常见的抗癌药物缺乏选择性。解决此问题的方法是抗体导向的酶前药疗法（ADEPT）和前药单一疗法（PMT）。在此，描述了适用于两个概念的新糖苷前药的合成和生物学评估。所有前药，但一个是人血清中稳定，并显示QIC 50个值（IC 50前药/ IC 50的前药在适当的糖水解酶的存在的）向上至6500。这是最好的值为止找到的与DNA相互作用的化合物。

  DOI：

  10.1002/chem.201002798

文献信息

• Process for the preparation of protected mono-sugar and oligo-sugar
  申请人：Ciba-Geigy Corporation

  公开号：US05218097A1

  公开（公告）日：1993-06-08

  The reaction of protected monosaccharides or oligosaccharides or protected monosaccharide and oligosaccharide derivatives containing an anomeric hydroxyl group with secondary .alpha.-haloenamines affords high yields of protected glycosyl halides, which are valuable intermediates for the introduction of sugar groups in the synthesis of oligosaccharides, glycolipids or glycopeptides.

  受保护的单糖或寡糖，或含有环状羟基的受保护单糖和寡糖衍生物与次级α-卤胺发生反应，生成受保护的糖卤化物，其产率高，是在合成寡糖、糖脂或糖肽中引入糖基的宝贵中间体。
• Synthesis of chlorophenol red glucuronic acid
  申请人：——

  公开号：US20020115128A1

  公开（公告）日：2002-08-22

  This invention provides &bgr;-D-Glucuronidase substrates of the formula: 1 wherein R 1 , R 2 , and R 7 -R 12 are independently selected from the group consisting of: hydrogen, fluorine, chlorine, bromine, iodine, alkyl, hydroxyl, alkoxy, carboxyl and nitro groups; R 3 -R 6 are independently selected from the group consisting of hydrogen, fluorine, chlorine, bromine, iodine, nitro and amino; and M + is selected from the group consisting of: proton, lithium, sodium, potassium, magnesium, calcium, barium, and ammonium ion.

  这项发明提供了β-D-葡萄糖醛酸酶底物的结构式如下：其中R1、R2和R7-R12分别独立地选择自氢、氟、氯、溴、碘、烷基、羟基、烷氧基、羧基和硝基基团组成的群体；R3-R6分别独立地选择自氢、氟、氯、溴、碘、硝基和氨基组成的群体；以及M+选择自质子、锂、钠、钾、镁、钙、钡和铵离子组成的群体。
• [EN] A PROCESS FOR MAKING MORPHINE-6-GLUCURONIDE OR SUBSTITUTED MORPHINE-6-GLUCURONIDE
  申请人：SALFORD ULTRAFINE CHEMICALS AND RESEARCH LIMITED

  公开号：WO1993003051A1

  公开（公告）日：1993-02-18

  (EN) Morphine-6-glucuronide or substituted morphine-6-glucuronide of formulae (I) is made by conjugation of a glucuronate ester and/or substituted glucuronate ester with morphine or substituted morphine in the presence of a Lewis acid catalyst and in the absence of silver catalysts and barium hydroxide and other heavy metal derivatives.(FR) On prépare de la morphine-6-glycuroconjuguée ou de la morphine-6-glycuroconjuguée substituée représentées par les formules (I) en conjuguant un ester de glycuroconjugué et/ou un ester de glycuroconjugé substitué avec de la morphine ou de la morphine substituée en présence d'un catalyseur d'acide de Lewis et en l'absence de catalyseurs à l'argent et de baryte hydratée et d'autres dérivés de métaux lourds.

  Morphine-6-glucuronide或式(I)的取代morphine-6-glucuronide是通过在Lewis酸催化剂的存在下，将glucuronate酯和/或取代的glucuronate酯与morphine或取代的morphine结合而成，并且不含银催化剂、氢氧化钡和其他重金属衍生物。
• ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS
  申请人：DeVita Robert J.

  公开号：US20100035857A1

  公开（公告）日：2010-02-11

  This invention provides cholesterol absorption inhibitors of Formula I:I and the pharmaceutically acceptable salts thereof. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating and preventing atherosclerosis and atherosclerotic disease events.

  本发明提供了I式的胆固醇吸收抑制剂及其药学上可接受的盐。这些化合物可用于降低血浆胆固醇水平，特别是低密度脂蛋白胆固醇，并用于治疗和预防动脉粥样硬化和动脉粥样硬化性疾病事件。
• Ellipticine derivative and production process thereof
  申请人：SUNTORY LIMITED

  公开号：EP0173462A2

  公开（公告）日：1986-03-05

  An ellipticine derivative having the general formula: wherein R represents a hydrogen atom, a hydroxyl group, an alkoxyl group having 1 to 4 carbon atoms, or an acyloxy group having 2 to 7 carbon atoms; R2 represents an aldose residue, a deoxyaldose residue, an N-acylaminoaldose residue having a substituted acyl group with 2 to 4 carbon atoms bonded to the N atom, an aldohexuronic amide residue, and aldohexuronic acid residue, an acylated aldose residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an alkylacyl group with 2 to 4 carbon atoms or an arylacyl group with 7 to 9 carbon atoms, an acylated deoxyaldose residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an alkylacyl group with 2 to 4 carbon atoms or an arylacyl group with 7 to 9 carbon atoms, an acylated N-acylaminoaldose residue having an amino group substituted with an acyl group with 2 to 4carbon atoms and having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an alkylacyl group with 2 to 4 carbon atoms or an arylacyl group with 7 to 9 carbon atoms, an acylated aldohexuronic amide residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an alkylacyl group with 2 to 4 carbon atoms or an arylacyl group with 7 to 9 carbon atoms, an acylated aldohexuronic acid residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an alkylacyl group with 2 to 4 carbon atoms or an arylacyl group with 7 to 9 carbon atoms, an acylated aldohexuronic acid ester residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an alkylacyl group with 2 to 4 carbon atoms or an arylacyl group with 7 to 9 carbon atoms, an arylalkylated aldose residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an arylalkyl group with 7 to 8 carbon atoms, an arylalkylated deoxyaldose residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an alkylacyl group with 7 to 8 carbon atoms, an arylalkylated N-acylaminoaldose residue having an amino group with an acyl group with 2 to 4 carbon atoms and having, substituted for the hydrogen of the hydroxyl group of the sugar, an arylalkyl group with 7 to 8 carbon atoms, an arylalkylated aldohexuronic amide residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an arylalkyl group with 7 to 8 carbon atoms, an arylalkylated aldohexuronic acid residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an arylalkyl group with 7 to 8 carbon atoms, an arylalkylated aldohexuronic acid ester residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an arylalkyl group with 7 to 8 carbon atoms; and R3 represents a hydrogen atom, a linear, branched, cyclic, or cyclic-linear alkyl group having 1 to 5 carbon atoms; X0 represents a pharmaceutically acceptable inorganic or organic acid anion; and the bond represented by N⊕ - R2 in the general formula (I) represents a glycoside bond between a nitrogen atom in the 2-position of the ellipticine and a carbon atom in the 1-position of the sugar. These ellipticine derivatives have a strong antineoplastic or antitumor activity and, therefore, are expected to be effective as an antineoplastic or antitumor agent.

  一种具有通式的鞣花碱衍生物： 其中 R 代表氢原子、羟基、具有 1 至 4 个碳原子的烷氧基或具有 2 至 7 个碳原子的酰氧基； R2 代表醛糖残基、脱氧醛糖残基、N-酰氨基醛糖残基（其 N 原子上键有 2 至 4 个碳原子的取代酰基）、醛缩脲酰胺残基、醛缩脲酸残基、酰化醛糖残基（其糖羟基的氢原子被取代）、一种酰化脱醛糖残基，其糖羟基的氢原子被 2 至 4 个碳原子的烷酰基或 7 至 9 个碳原子的芳酰基取代、酰化的 N-酰氨基醛糖残基，其氨基被 2 至 4 个碳原子的酰基取代，并具有 2 至 4 个碳原子的烷酰基或 7 至 9 个碳原子的芳酰基取代糖羟基的氢原子；酰化的醛缩酰胺残基，其具有一种酰化的醛缩己脲酰胺残基，其糖的羟基的氢原子被 2 至 4 个碳原子的烷酰基或 7 至 9 个碳原子的芳酰基取代、酰化醛缩醛酸酯残基，其糖羟基的氢原子被 2 至 4 个碳原子的烷基酰基或 7 至 9 个碳原子的芳基酰基取代、芳烷基化脱醛糖残基，其糖的羟基的氢原子被 7 至 8 个碳原子的烷酰基取代；芳烷基化 N-酰氨基醛糖残基，其氨基带有 2 至 4 个碳原子的酰基，并具有一种芳烷基化的醛缩脲酰胺残基，其氨基具有 2 至 4 个碳原子的酰基，并具有 7 至 8 个碳原子的芳烷基取代糖的羟基的氢原子、一种芳烷基化的醛缩脲酸酯残基，其糖的羟基的氢原子被具有 7 至 8 个碳原子的芳烷基取代；和 R3 代表氢原子、具有 1 至 5 个碳原子的直链、支链、环状或环状直链烷基； X0 代表药学上可接受的无机或有机酸阴离子；以及 通式（I）中 N⊕ - R2 所代表的键代表鞣花碱 2 位上的氮原子与糖 1 位上的碳原子之间的糖苷键。这些鞣花碱衍生物具有很强的抗肿瘤或抗肿瘤活性，因此有望成为有效的抗肿瘤或抗肿瘤药物。